Two birds with one stone? Possible dual-targeting H1N1 inhibitors from traditional Chinese medicine

PLoS Computational Biology

Volumn 7, Issue 12, 2011, Pages

  Chang, Su Sen ^a   Huang, Hung Jin ^a   Chen, Calvin Yu Chian ^a,b,c,d,e  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b ASIA UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY BEIGANG HOSPITAL   (Taiwan)

^d HARVARD MEDICAL SCHOOL   (United States)

^e Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG THERAPY; HYDROPHOBICITY; LEARNING SYSTEMS; MEDICINE; VIRUSES;

'CURRENT; DRUG-RESISTANCE; DYNAMICS SIMULATION; HYDROPHOBIC INTERACTIONS; INFLUENZA PANDEMICS; MACHINE-LEARNING; MULTIPLE MACHINE; PREDICTION MODELLING; PYRIDINIUM; TRADITIONAL CHINESE MEDICINE;

MOLECULAR DYNAMICS;

ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; CHINESE DRUG; OSELTAMIVIR; PYRIDINIUM DERIVATIVE; ROSMARICINE 11; ROSMARICINE 12; ROSMARICINE 14; ROSMARICINE 15; ROSMARICINE 16; ROSMARICINE 21; ROSMARICINE 23; ROSMARICINE 5; ROSMARICINE 6; UNCLASSIFIED DRUG; XYLOPINE; XYLOPINE 2; APORPHINE DERIVATIVE; DITERPENE; HERBACEOUS AGENT; ROSMARICINE;

AMINO ACID SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CHINESE MEDICINE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG BINDING; DRUG MECHANISM; DRUG SCREENING; DRUG STABILITY; DRUG STRUCTURE; DRUG TARGETING; HYDROGEN BOND; HYDROPHOBICITY; INFLUENZA VIRUS A H1N1; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR DYNAMICS; PROTEIN INTERACTION; SIMULATION; STRUCTURE ANALYSIS; VIRUS INHIBITION; VIRUS MUTATION; ANTIVIRAL RESISTANCE; ARTIFICIAL INTELLIGENCE; CHEMISTRY; DRUG EFFECT; FACTUAL DATABASE; GENETICS; HUMAN; INFLUENZA; MUTATION; SUPPORT VECTOR MACHINE; VIROLOGY;

AVES;

ANTIVIRAL AGENTS; APORPHINES; ARTIFICIAL INTELLIGENCE; DATABASES, FACTUAL; DITERPENES; DRUG RESISTANCE, VIRAL; DRUGS, CHINESE HERBAL; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MEDICINE, CHINESE TRADITIONAL; MOLECULAR DYNAMICS SIMULATION; MUTATION; SUPPORT VECTOR MACHINES;

EID: 84855282742     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1002315     Document Type: Article

References (109)

1. World Health Organization (2009) WHO statement: World now at the start of 2009 influenza pandemic. Available at http://www.who.int/mediacentre/news/statements/2009/h1n1_pandemic_phase6_20090611/en/index.html Accessed 5 July 2011.
2. World Health Organization (2010) Pandemic (H1N1) 2009-Update 112. WHO Global Alert and Response, Weekly Update Available at http://www.who.int/csr/don/2010_08_06/en/index.html Accessed 5 July 2011.
3. Uyeki T, (2009) Antiviral treatment for patients hospitalized with 2009 pandemic influenza A (H1N1). N Engl J Med 361: e110.
4. Layne SP, Monto AS, Taubenberger JK, (2009) Pandemic influenza: an inconvenient mutation. Science 323: 1560-1561.
5. Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, et al. (2000) Efficacy and safety of oseltamivir in treatment of acute influenza: A randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 355: 1845-1850.
6. Skehel J, (2009) An overview of influenza haemagglutinin and neuraminidase. Biologicals 37: 177-178.
7. Betakova T, (2007) M2 protein-a proton channel of influenza A virus. Curr Pharm Des 13: 3231-3235.
8. Suzuki Y, Nagao Y, Kato H, Matsumoto M, Nerome K, et al. (1986) Human influenza A virus hemagglutinin distinguishes sialyloligosaccharides in membrane-associated gangliosides as its receptor which mediates the adsorption and fusion processes of virus infection. Specificity for oligosaccharides and sialic acids and the sequence to which sialic acid is attached. J Biol Chem 261: 17057-17061.
9. Hartshorn KL, Liou LS, White MR, Kazhdan MM, Tauber JL, et al. (1995) Neutrophil deactivation by influenza A virus. Role of hemagglutinin binding to specific sialic acid-bearing cellular proteins. J Immunol 154: 3952-3960.
10. Qi L, Kash JC, Dugan VG, Wang R, Jin G, et al. (2009) Role of sialic acid binding specificity of the 1918 influenza virus hemagglutinin protein in virulence and pathogenesis for mice. J Virol 83: 3754-3761.
11. Seto JT, Brzeniek R, Rott R, (1966) Isolation of a low molecular weight sialidase (neuraminidase) from influenza virus. Biochimica et Biophysica Acta 113: 402-404.
12. Triana-Baltzer GB, Gubareva LV, Klimov AI, Wurtman DF, Moss RB, et al. (2009) Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. PLoS One 4: e7838.
13. Pielak RM, Chou JJ, (2011) Influenza M2 proton channels. Biochimica et Biophysica Acta 1808: 522-529.
14. Salomon R, Webster RG, (2009) The influenza virus enigma. Cell 136: 402-410.
15. Schnell JR, Chou JJ, (2008) Structure and mechanism of the M2 proton channel of influenza A virus. Nature 451: 591-595.
16. Wang J, Pielak RM, McClintock MA, Chou JJ, (2009) Solution structure and functional analysis of the influenza B proton channel. Nat Struct Mol Biol 16: 1267-1271.
17. Pielak RM, Chou JJ, (2010) Kinetic analysis of the M2 proton conduction of the influenza virus. J Am Chem Soc 132: 17695-17697.
18. Pielak RM, Schnell JR, Chou JJ, (2009) Mechanism of drug inhibition and drug resistance of influenza A M2 channel. Proc Natl Acad Sci U S A 106: 7379-7384.
19. Huang RB, Du QS, Wang CH, Chou KC, (2008) An in-depth analysis of the biological functional studies based on the NMR M2 channel structure of influenza A virus. Biochem Biophys Res Commun 377: 1243-1247.
20. Du QS, Huang RB, Wang SQ, Chou KC, (2010) Designing inhibitors of M2 proton channel against H1N1 swine influenza virus. PLoS One 5: e9388.
21. Wang J, Qiu JX, Soto C, DeGrado WF, (2011) Structural and dynamic mechanisms for the function and inhibition of the M2 proton channel from influenza A virus. Curr Opin Struct Biol 21: 68-80.
22. Rajik M, Yusoff K, (2011) Peptide inhibitors against influenza virus. Antivir Chem Chemother 21: 151-154.
23. Balannik V, Wang J, Ohigashi Y, Jing X, Magavern E, et al. (2009) Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus. Biochemistry 48: 11872-11882.
24. Shen YF, Chen YH, Chu SY, Lin MI, Hsu HT, et al. (2011) E339..R416 salt bridge of nucleoprotein as a feasible target for influenza virus inhibitors. Proc Natl Acad Sci U S A 108: 16515-16520.
25. Wang J, Ma C, Wu Y, Lamb RA, Pinto LH, et al. (2011) Exploring organosilane amines as potent inhibitors and structural probes of influenza a virus M2 proton channel. J Am Chem Soc 133: 13844-13847.
26. Rungrotmongkol T, Yotmanee P, Nunthaboot N, Hannongbua S, (2011) Computational studies of influenza A virus at three important targets: hemagglutinin, neuraminidase and M2 protein. Curr Pharm Des 17: 1720-1739.
27. Du QS, Wei H, Huang RB, Chou KC, (2011) Progress in structure-based drug design against influenza A virus. Expert Opin Drug Discovery 6: 619-631.
28. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, et al. (2009) Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 325: 197-201.
29. McDonald NJ, Smith CB, Cox NJ, (2007) Antigenic drift in the evolution of H1N1 influenza A viruses resulting from deletion of a single amino acid in the haemagglutinin gene. J Gen Virol 88: 3209-3213.
30. Boni MF, (2008) Vaccination and antigenic drift in influenza. Vaccine 26 (Suppl 3): C8-14.
31. Treanor J, (2004) Influenza vaccine-Outmaneuvering antigenic shift and drift. The N Engl J Med 350: 218-220.
32. Kitahori Y, Nakano M, Inoue Y, (2006) Frequency of amantadine-resistant Influenza A Virus isolated from 2001-02 to 2004-05 in Nara Prefecture. Jpn J Infect Dis 59: 197-199.
33. Cheng PK, Leung TW, Ho EC, Leung PC, Ng AY, et al. (2009) Oseltamivir- and amantadine-resistant influenza viruses A (H1N1). Emerg Infect Dis 15: 966-968.
34. World Health Organization (2009) Oseltamivir-resistant pandemic (H1N1) 2009 influenza virus, October 2009. Weekly Epidemiological Record 84: 453-468 Available at http://www.who.int/wer/2009/wer8444/en/index.html Accessed 2006 August 2011.
35. Baranovich T, Saito R, Suzuki Y, Zaraket H, Dapat C, et al. (2010) Emergence of H274Y oseltamivir-resistant A(H1N1) influenza viruses in Japan during the 2008-2009 season. J Clin Virol 47: 23-28.
36. Pielak RM, Chou JJ, (2010) Flu channel drug resistance: a tale of two sites. Protein Cell 1: 246-258.
37. Wang J, Ma C, Fiorin G, Carnevale V, Wang T, et al. (2011) Molecular dynamics simulation directed rational design of inhibitors targeting drug-resistant mutants of influenza a virus M2. J Am Chem Soc 133: 12834-12841.
38. Mai BK, Li MS, (2011) Neuraminidase inhibitor R-125489-a promising drug for treating influenza virus: steered molecular dynamics approach. Biochem Biophys Res Commun 410: 688-691.
39. Leonov H, Astrahan P, Krugliak M, Arkin IT, (2011) How do aminoadamantanes block the influenza M2 channel, and how does resistance develop? J Am Chem Soc 133: 9903-9911.
40. Yang JR, Lin YC, Huang YP, Su CH, Lo J, et al. (2011) Reassortment and mutations associated with emergence and spread of oseltamivir-resistant seasonal influenza A/H1N1 viruses in 2005-2009. PLoS One 6: e18177.
41. He Z, Zhang J, Shi XH, Hu LL, Kong X, et al. (2010) Predicting drug-target interaction networks based on functional groups and biological features. PLoS One 5: e9603.
42. Saven JG, (2011) Computational protein design: engineering molecular diversity, nonnatural enzymes, nonbiological cofactor complexes, and membrane proteins. Curr Opin Chem Biol 15: 452-457.
43. Vanhee P, van der Sloot AM, Verschueren E, Serrano L, Rousseau F, et al. (2011) Computational design of peptide ligands. Trends Biotechnol 29: 231-239.
44. Morin A, Meiler J, Mizoue LS, (2011) Computational design of protein-ligand interfaces: potential in therapeutic development. Trends Biotechnol 29: 159-166.
45. Huang T, Shi XH, Wang P, He Z, Feng KY, et al. (2010) Analysis and prediction of the metabolic stability of proteins based on their sequential features, subcellular locations and interaction networks. PLoS One 5: e10972.
46. Wang P, Hu L, Liu G, Jiang N, Chen X, et al. (2011) Prediction of antimicrobial peptides based on sequence alignment and feature selection methods. PLoS One 6: e18476.
47. Chou KC, (2004) Structural bioinformatics and its impact to biomedical science. Curr Med Chem 11: 2105-2134.
48. Chen CY, Chang YH, Bau DT, Huang HJ, Tsai FJ, et al. (2009) Discovery of potent inhibitors for phosphodiesterase 5 by virtual screening and pharmacophore analysis. Acta pharmacologica Sinica 30: 1186-1194.
49. Chen CYC, (2010) Bioinformatics, chemoinformatics, and pharmainformatics analysis of HER2/HSP90 dual-targeted inhibitors. Journal of the Taiwan Institute of Chemical Engineers 41: 143-149.
50. Huang HJ, Chen CY, Chen CY, Tsai FJ, Chen CYC, (2010) Computational screening and QSAR analysis for design of AMP-activated protein kinase agonist. Journal of the Taiwan Institute of Chemical Engineers 41: 352-359.
51. Wang SQ, Du QS, Huang RB, Zhang DW, Chou KC, (2009) Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus. Biochem Biophys Res Commun 386: 432-436.
52. Chou KC, Wei DQ, Du QS, Sirois S, Zhong WZ, (2006) Progress in computational approach to drug development against SARS. Curr Med Chem 13: 3263-3270.
53. Glen RC, Allen SC, (2003) Ligand-protein docking: cancer research at the interface between biology and chemistry. Curr Med Chem 10: 763-767.
54. Yuriev E, Agostino M, Ramsland PA, (2011) Challenges and advances in computational docking: 2009 in review. J Mol Recognit 24: 149-164.
55. Zhou GP, (2011) The disposition of the LZCC protein residues in wenxiang diagram provides new insights into the protein-protein interaction mechanism. J Theor Biol 284: 142-148.
56. Zhou GP, (2011) The structural determinations of the leucine zipper coiled-coil domains of the cGMP-dependent protein kinase Ialpha and its interaction with the myosin binding subunit of the myosin light chains phosphase. Protein Pept Lett 18: 966-978.
57. Bjorndahl TC, Zhou GP, Liu X, Perez-Pineiro R, Semenchenko V, et al. (2011) Detailed biophysical characterization of the acid-induced PrP(c) to PrP(beta) conversion process. Biochemistry 50: 1162-1173.
58. Chou KC, Chen NY, (1977) The biological functions of low-frequency phonons. Scientia Sinica 20: 447-457.
59. Chou KC, (1983) Identification of low-frequency modes in protein molecules. Biochem J 215: 465-469.
60. Chou KC, (1985) Low-frequency motions in protein molecules. Beta-sheet and beta-barrel. Biophys J 48: 289-297.
61. Chou KC, (1989) Low-frequency resonance and cooperativity of hemoglobin. Trends Biochem Sci 14: 212-213.
62. Martel P, (1992) Biophysical aspects of neutron scattering from vibrational modes of proteins. Prog Biophys Mol Biol 57: 129-179.
63. Chou KC, (1988) Low-frequency collective motion in biomacromolecules and its biological functions. Biophys Chem 30: 3-48.
64. Chou JJ, Li S, Klee CB, Bax A, (2001) Solution structure of Ca(2+)-calmodulin reveals flexible hand-like properties of its domains. Nat Struct Biol 8: 990-997.
65. Gordon GA, (2007) Designed electromagnetic pulsed therapy: clinical applications. J Cell Physiol 212: 579-582.
66. Gordon GA, (2008) Extrinsic electromagnetic fields, low frequency (phonon) vibrations, and control of cell function: a non-linera resonance system. Journal of Biomedical Science and Engineering 1: 152-156.
67. Madkan A, Blank M, Elson E, Chou KC, Geddis MS, et al. (2009) Steps to the clinic with ELF EMF Natural Science 1: 157-165.
68. Li Y, Zhang J, He D, Liang Q, Wang Y, (2011) Characterization of molecular recognition of phosphoinositide-3-kinase alpha inhibitor through molecular dynamics simulation. J Mol Model In press, DOI: 10.1007/s00894-011-1211-4.
69. Turra KM, Pasqualoto KF, Ferreira EI, Rando DG, (2011) Molecular modeling approach to predict a binding mode for the complex methotrexate-carboxypeptidase G(2). J Mol Model In press, DOI: 10.1007/s00894-011-1196-z.
70. Wang JF, Chou KC, (2011) Insights from modeling the 3D structure of New Delhi metallo-beta-lactamse and its binding interactions with antibiotic drugs. PLoS One 6: e18414.
71. Chen YC, (2007) The molecular dynamic simulation of zolpidem interaction with gamma aminobutyric acid type A receptor. J Chinese Chem Soc 54: 653-658.
72. Bjarnadottir U, Nielsen JE, (2012) Predicting the open conformations of protein kinases using molecular dynamics simulations. Biopolymers 97: 65-71.
73. da Costa AL, Pauli I, Dorn M, Schroeder EK, Zhan CG, et al. (2011) Conformational changes in 2-trans-enoyl-ACP (CoA) reductase (InhA) from M. tuberculosis induced by an inorganic complex: a molecular dynamics simulation study. J Mol Model In press, DOI: 10.1007/s00894-011-1200-7.
74. Wang JF, Chou KC, (2010) Insights from studying the mutation-induced allostery in the M2 proton channel by molecular dynamics. Protein Eng Des Sel 23: 663-666.
75. Lian P, Wei DQ, Wang JF, Chou KC, (2011) An allosteric mechanism inferred from molecular dynamics simulations on phospholamban pentamer in lipid membranes. PLoS One 6: e18587.
76. Zhang H, Qin F, Ye W, Li Z, Ma S, et al. (2011) Revealing the drug-resistant mechanism for diarylpyrimidine analogue inhibitors of HIV-1 reverse transcriptase. Chem Biol Drug Des 78: 427-437.
77. Chou KC, Wei DQ, Zhong WZ, (2003) Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS. Biochem Biophys Res Commun 308: 148-151.
78. Bocchinfuso G, Bobone S, Mazzuca C, Palleschi A, Stella L, (2011) Fluorescence spectroscopy and molecular dynamics simulations in studies on the mechanism of membrane destabilization by antimicrobial peptides. Cell Mol Life Sci 68: 2281-2301.
79. Chen CYC, Chen GW, Chen WYC, (2008) Molecular simulation of HER2/neu degradation by inhibiting HSP90. J Chinese Chem Soc 55: 297-302.
80. Wang JF, Gong K, Wei DQ, Li YX, Chou KC, (2009) Molecular dynamics studies on the interactions of PTP1B with inhibitors: from the first phosphate-binding site to the second one. Protein Eng Des Sel 22: 349-355.
81. Cui Y, (2011) Using molecular simulations to probe pharmaceutical materials. J Pharm Sci 100: 2000-2019.
82. Stanton RA, Gernert KM, Nettles JH, Aneja R, (2011) Drugs that target dynamic microtubules: a new molecular perspective. Med Res Rev 31: 443-481.
83. Prevelige PE Jr, (2011) New approaches for antiviral targeting of HIV assembly. J Mol Biol 410: 634-640.
84. Chen CY, Chen CYC, (2010) Insights into designing the dual-targeted HER2/HSP90 inhibitors. J Mol Graph Model 29: 21-31.
85. Fedichev P, Timakhov R, Pyrkov T, Getmantsev E, Vinnik A, (2011) Structure-based drug design of a new chemical class of small molecules active against influenza A nucleoprotein in vitro and in vivo. PLoS Curr 3: RRN1253.
86. Kirchmair J, Distinto S, Liedl KR, Markt P, Rollinger JM, et al. (2011) Development of anti-viral agents using molecular modeling and virtual screening techniques. Infect Disord Drug Targets 11: 64-93.
87. Le L, Lee EH, Hardy DJ, Truong TN, Schulten K, (2010) Molecular dynamics simulations suggest that electrostatic funnel directs binding of Tamiflu to influenza N1 neuraminidases. PLoS Comput Biol 6: e1000939.
88. Wang JF, Wei DQ, Chou KC, (2008) Drug candidates from traditional chinese medicines. Curr Top Med Chem 8: 1656-1665.
89. Chen CYC, (2011) TCM Database@Taiwan: the World's largest traditional Chinese medicine database for drug screening in silico. PLoS One 6: e15939.
90. Chen CY, Chang YH, Bau DT, Huang HJ, Tsai FJ, et al. (2009) Ligand-based dual target drug design for H1N1: Swine flu-A preliminary first study. J Biomol Struct Dyn 27: 171-178.
91. Chen CY, Huang HJ, Tsai FJ, Chen CYC, (2010) Drug design for influenza A virus subtype H1N1. Journal of the Taiwan Institute of Chemical Engineers 41: 8-15.
92. Chang T-T, Sun M-F, Chen H-Y, Tsai F-J, Chen CY-C, (2011) Drug design for hemagglutinin: Screening and molecular dynamics from traditional Chinese medicine database. J Chinese Inst Chem Eng 42: 563-571.
93. Chang T-T, Sun M-F, Chen H-Y, Tsai F-J, Fisher M, et al. (2011) Screening from the World's largest TCM database for against H1N1 virus. J Biomol Struct Dyn 28: 773-786.
94. Lai C-Y, Chang T-T, Sun M-F, Chen H-Y, Tsai F-J, et al. (2011) Molecular dynamics analysis of potent inhibitors of M2 proton channel against H1N1 swine influenza virus. Mol Simulat 37: 250-256.
95. Lin C-H, Chang T-T, Sun M-F, Chen H-Y, Tsai F-J, et al. (2011) Potent inhibitor design against H1N1swine influenza: Structure-based and molecular dynamics analysis for M2 inhibitors fromtraditional Chinese medicine database. J Biomol Struct Dyn 28: 471-482.
96. Oluwatuyi M, Kaatz GW, Gibbons S, (2004) Antibacterial and resistance modifying activity of Rosmarinus officinalis. Phytochemistry 65: 3249-3254.
97. Montenegro H, Gutierrez M, Romero LI, Ortega-Barria E, Capson TL, et al. (2003) Aporphine alkaloids from Guatteria spp. with leishmanicidal activity. Planta Medica 69: 677-679.
98. Russell RJ, Haire LF, Stevens DJ, Collins PJ, Lin YP, et al. (2006) The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 443: 45-49.
99. von Itzstein M, (2007) The war against influenza: Discovery and development of sialidase inhibitors. Nat Rev Drug Discov 6: 967-974.
100. Stevens J, Corper AL, Basler CF, Taubenberger JK, Palese P, et al. (2004) Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science 303: 1866-1870.
101. Liu AL, Wang HD, Lee SMY, Wang YT, Du GH, (2008) Structure-activity relationship of flavonoids as influenza virus neuraminidase inhibitors and their in vitro anti-viral activities. Bioorg Med Chem 16: 7141-7147.
102. Zhang Q, Yang J, Liang K, Feng L, Li S, et al. (2008) Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling. J Chem Inf Model 48: 1802-1812.
103. Moscona A, (2009) Global transmission of oseltamivir-resistant influenza. N Engl J Med 360: 953-956.
104. Morlighem JE, Aoki S, Kishima M, Hanami M, Ogawa C, et al. (2011) Mutation analysis of 2009 pandemic influenza A(H1N1) viruses collected in Japan during the peak phase of the pandemic. PLoS One 6: e18956.
105. Brooks BR, Brooks CL 3rd, Mackerell AD Jr, Nilsson L, Petrella RJ, et al. (2009) CHARMm: The biomolecular simulation program. J Comput Chem 30: 1545-1614.
106. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ, (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev 46: 3-26.
107. Rogers D, Hopfinger AJ, (1994) Application of genetic function approximation to quantitative structure-activity relationships and quantitative structure-property relationships. J Chem Inf Model 34: 854-866.
108. Chang CC, Lin CJ, (2011) LIBSVM, A library for support vector machines. ACM Transactions on Intelligent Systems and Technology 2: 27:21-27:27.
109. Wallace AC, Laskowski RA, Thornton JM, (1995) LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng 8: 127-134.